Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib

Assessment of therapy response to Regorafenib by 18F-DOPA-PET/CT in patients with recurrent high-grade gliomas: a case series

(2021) Eugenio Di Giorgio et al.   Clinical and Translational Imaging

Modification of MRI pattern of high‐grade glioma pseudoprogression in regorafenib therapy

(2021) Mariam Mansour et al.   Journal of Medical Imaging and Radiation Oncology

PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction

(2021) Giuseppe Lombardi et al.   BRITISH JOURNAL OF RADIOLOGY

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

(2018) Giuseppe Lombardi et al.   LANCET ONCOLOGY

Advances in neuro-oncology imaging

(2017) Karl-Josef Langen et al.   Nature Reviews Neurology

Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma

(2016) H.S. Nguyen et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls

(2012) S. Mong et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY